We are proud to announce that MonTa Biosciences has been granted patents in Israel, China, and Japan covering our lead cancer immunotherapy candidate, MBS8.
These newly issued patents strengthen our global intellectual property portfolio and provide broad protection for MBS8 — a novel TLR7 agonist formulated in micelles with best-in-class potential. MBS8 is designed to stimulate the innate immune system to fight cancer and is currently progressing through clinical development.
Securing patent rights in these important regions is a major milestone as we continue to advance MBS8 towards commercialization and expand our international footprint. With granted patents now in several key markets, MonTa is well-positioned to deliver innovation to cancer patients worldwide.
We remain committed to transforming the treatment landscape through immune system education — aiming not just to extend life, but to cure.